FLLL32

Catalog No.S7259 Batch:S725901

Print

Technical Data

Formula

C28H32O6
Molecular Weight 464.55 CAS No. 1226895-15-3
Solubility (25°C)* In vitro DMSO 92 mg/mL (198.04 mM)
Ethanol 25 mg/mL (53.81 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.8mg/ml Taking the 1 mL working solution as an example, add 50 μL of 16 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.
Targets
JAK2 [1]
<5 μM
In vitro In MDA-MB-231 breast and PANC-1 pancreatic cancer cells, FLLL32 downregulates STAT3 phosphorylation and DNA-binding activity. In MDA-MB-231 cells, FLLL32 inhibit the formation of colonies and cell invasion. [1] In human multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cell lines, FLLL32 also leads to the inhibition of cell proliferation and the induction of caspase-3 and PARP cleavages. [2]
In vivo In MDA-MB-231 xenografted mice, FLLL32 (50 mg/kg, i.p.) significantly reduces tumor burdens. [1] In mouse xenografts with OS-33 osteosarcoma cells, FLLL32 (50 mg/kg, i.p.) also inhibits tumor growth by targeting STAT3. [3]

Protocol (from reference)

Kinase Assay:[1]
  • JAK2 and other human kinase activity assays

    JAK2 kinase activity was assessed with the HTScan JAK2 Kinase Assay Kit per manufacturer's protocol. The possible effects of FLLL32 on the other 10 purified human protein kinases were determined by using a Kinase Profiler Assay.
Cell Assay:[1]
  • Cell lines

    MDA-MB-231 cell line

  • Concentrations

    ~5 μM

  • Incubation Time

    72 hours

  • Method

    Cells are seeded in 96-well plates (3,000 per well) in triplicate and then treated with 0.5 to 5 μM of FLLL31 or FLLL32 or with 0.5 to 30 μM of curcumin for 72 h. MTT (25 μL) is added to each sample and incubated for 3.5 h. Then, 100 μL of N,N-dimethylformamide solubilization solution are added to each well. The absorbance at 450 nm is read the following day. IC50 are determined using Sigma Plot 9.0 software.
Animal Study:[1]
  • Animal Models

    MDA-MB-231 xenografted mice

  • Dosages

    50 mg/kg, daily

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , Cancer Sci, 2016, 107(7):944-54. ]

Data from [Data independently produced by , , Eur Rev Med Pharmacol Sci, 2017, 21(13):3005-3011]

Selleck's FLLL32 has been cited by 12 publications

JARID2 coordinates with the NuRD complex to facilitate breast tumorigenesis through response to adipocyte-derived leptin [ Cancer Commun -Lond), 2023, 43(10):1117-1142] PubMed: 37658635
Melatonin attenuates chronic intermittent hypoxia-induced intestinal barrier dysfunction in mice [ Microbiol Res, 2023, 276:127480] PubMed: 37659335
RING-Finger Protein 6 promotes Drug Resistance in Retinoblastoma via JAK2/STAT3 Signaling Pathway [ Pathol Oncol Res, 2022, 28:1610273] PubMed: 35369571
Regulation of STUB1 expression and its biological significance in mouse Sertoli cells [ Syst Biol Reprod Med, 2022, 1-15] PubMed: 35343345
Protective and anti-inflammatory role of REG1A in inflammatory bowel disease induced by JAK/STAT3 signaling axis [ Int Immunopharmacol, 2021, 92:107304] PubMed: 33513463
Aberrant SLC6A14 Expression Promotes Proliferation and Metastasis of Colorectal Cancer via Enhancing the JAK2/STAT3 Pathway [ Onco Targets Ther, 2021, 14:379-392] PubMed: 33469314
Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis [ Transl Oncol, 2020, 13(10):100825] PubMed: 32698059
B7-H3 Regulates Glioma Growth and Cell Invasion Through a JAK2/STAT3/Slug-Dependent Signaling Pathway. [ Onco Targets Ther, 2020, 12;13:2215-2224] PubMed: 32210587
Downregulation of DPF3 promotes the proliferation and motility of breast cancer cells through activating JAK2/STAT3 signaling. [ Biochem Biophys Res Commun, 2019, 514(3):639-644] PubMed: 31076105
SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells. [Li MZ, et al. Eur Rev Med Pharmacol Sci, 2017, 21(13):3005-3011] PubMed: 28742207

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.